Lantheus Holdings (MIL:1LNTH) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1LNTH Lantheus Holdings Inc MIL:1LNTH
66 GF Score
Price €89.50
GF Value €75.12
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Lantheus Holdings FFO per Share?

FFO per Share only applies to REITs.

MIL:1LNTH
66GF Score
Lantheus Holdings Inc MIL:1LNTH
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lantheus Holdings (MIL:1LNTH) Overvalued in 2026?

Based on GuruFocus' analysis, Lantheus Holdings stock appears to be overvalued. The current stock price of €89.50 is trading 19.1% above its estimated GF Value™ of €75.12. GuruFocus considers Lantheus Holdings to be Modestly Overvalued.

Key valuation signals for MIL:1LNTH:

  • FFO per Share:
  • GF Value™: €75.12 vs. price of €89.50 (19.1% above fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the MIL:1LNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lantheus Holdings Business Description

Other Exchanges LNTH:USA0L8:Germany
Address 201 Burlington Road, South Building, Bedford, MA, USA, 01730
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
66GF Score

Get the complete analysis for MIL:1LNTH

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€89.50
Price
€75.12
GF Value